CTNND2

Across TCGA pan-cancer cohorts, CTNND2 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated CTNND2 data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher CTNND2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CTNND2 expression acts as an unfavorable survival marker, although some lineages such as SCLC and UCEC show a favorable association.

MESO, HNSC, and COAD are the cancer types where CTNND2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.130	0.557	.019	18	view →
HNSC	OS	Median	III,IV	0.147	0.687	<.001	18	view →
COAD	OS	Median	IV	0.039	0.650	<.001	15	view →
LUAD	OS	Median	III,IV	0.069	0.707	<.001	12	view →
SCLC	DFS	Median	All	0.799	0.430	.003	8	view →
DLBC	DFS	Median	All	0.022	0.809	<.001	6	view →
PAAD	OS	Median	All	0.131	0.640	.012	6	view →
UCS	OS	Median	All	0.185	0.686	.034	6	view →
ACC	OS	Median	II,III,IV	0.273	0.766	.033	6	view →
UCEC	DFS	Median	All	0.779	0.628	.027	6	view →
SKCM	OS	Median	IV	0.179	0.727	<.001	5	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

CTNND2–MESO (OS)

Open the MESO breakdown →